Barclays Maintains Underweight on LifeStance Health Gr, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Stephanie Davis maintains an Underweight rating on LifeStance Health Group (NASDAQ:LFST) and lowers the price target from $8 to $6.
August 09, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays analyst Stephanie Davis maintains an Underweight rating on LifeStance Health Group and lowers the price target from $8 to $6.
The Underweight rating and lowered price target from $8 to $6 by Barclays suggest a negative outlook on LifeStance Health Group's stock. This is likely to result in a short-term decline in the stock price as investors react to the downgraded expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100